Comparison of Two Different Combination Immunosuppressive Therapies in the Treatment of Vogt-Koyonagi-Harada Syndrome

Abstract

Purpose: To compare the efficacy and safety of cyclosporine/mycophenolate mofetil (CSA/MMF) and cyclosporine/azathioprine (CSA/AZT) in Vogt-Koyonagi-Harada (VKH) patients.

Methods: Retrospective comparative case series with follow-up period of at least 1 year. Outcomes include remission rate and corticosteroid-sparing effect.

Results: A total of 10 patients were included (5 patients in CSA/MMF, 5 patients in CSA/AZT). The remission rates for CSA/MMF and CSA/AZT were 5.3 and 5.6, respectively (p = .96). The median time to remission was 15 months for CSA/MMF group and 7 months for CSA/AZT group (p = .6419). The rates of corticosteroid-sparing effect were 7.9 and 5.0 for the CSA/MMF and CSA/AZT groups, respectively (p = .65). The median time to corticosteroid-sparing effect was faster in the CSA/AZT group (2 months) compared to the CSA/MMF group (13 months) (p = .9625). Approximately 50% of patients failed with the presented IMT combination regimens.

Conclusions: No statistically significant difference was found in the two regimens from the study as presented, although the median time to remission and to corticosteroid-sparing effect was shorter for the CSA/AZT combination.

KEYWORDS::

• Azathioprine
• Cyclosporine
• Immunosuppressive therapy
• Mycophenolate mofetil
• Vogt-Koyonagi-Harada (VKH) syndrome

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.